Full Press Release Details
SALT LAKE CITY,Dec. 9, 2025/PRNewswire/ --Co-Diagnostics, Inc. (Nasdaq:CODX)("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the Company is delivering a presentation at the Point-of-Care Testing 2025 Exhibition and Conference in Boston, MA.
The presentation, titled "Exploring the Promise of Portable, Cloud-Connected PCR Diagnostics," will unpack Co-Dx's move to portable PCR diagnostics to address evolving point-of-care needs, introduce the Company's upcoming Co-Dx PCR platform* and intuitive smartphone interface, and discuss how Co-Dx is harnessing AI to minimize user error and improve outcomes in real-time point-of-care testing.
TheConferenceprovides a forum for industry leaders and healthcare innovators to explore the latest breakthroughs in diagnostic testing, advanced technologies, and clinical strategies driving the future of patient-centered care. Agenda topics include trends in point-of-care diagnostics and patient-centered care strategies, innovative platforms for mobile testing and real-time health monitoring, the integration of AI and digital platforms in next-generation diagnostics, and advanced testing kits for infectious and chronic disease management.
The speaker session will be held at 11:30 AM EST at the Boston Marriott Cambridge in Massachusetts.
*The Co-Dx PCR platform (including the Co-Dx PCR Home™, Co-Dx PCR Pro™, mobile app, and all associated tests and software) is subject to review by the FDA and/or other regulatory bodies and is not available for sale.